RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS is the most
frequently mutated followed by NRAS. The emblematic KRAS mutant cancers are …

While cost-effective high-throughput technologies provide an increasing amount of data, the
analyses of single layers of data seldom provide causal relations. Multi-omics data …

Abstract Background and Purpose Survival rate of patients with lung cancer has increased
by over 60% in the recent two decades. With longer survival, the identification of genes …

Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer
(NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of …

KRAS signaling is associated with cancer progression in several cancers. Upregulation of
KRAS signaling is often seen in cancers that harbor high KRAS mutation rate, such as …

Large oncology repositories have paired genomic and transcriptomic data for all patients.
We used these data to perform two independent analyses: to identify gene expression …

Tumor heterogeneity is a major challenge for oncology drug discovery and development.
Understanding of the spatial tumor landscape is key to identifying new targets and impactful …

Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately
one-third of patients with NSCLC have a KRAS mutation. KRAS G12C, the most common …

Identifying genes with prognostic significance that can act as biomarkers in solid tumors can
help stratify patients and uncover novel therapy targets. Here, our goal was to expand our …

Whole exome sequencing (WES) enables the analysis of all protein coding sequences in
the human genome. This technology enables the investigation of cancer-related genetic …